Key result
Astaxanthin supplementation will be evaluated against placebo for its effects on arterial stiffness, oxidative stress, and inflammation in a planned randomized controlled trial of 66 renal transplant recipients over one year.
Why the study?
Does astaxanthin improve arterial stiffness, oxidative stress, and inflammation in renal transplant patients?
RCT (n=66)
Double-blind
Computer generated random numbers
Yes
Does astaxanthin improve arterial stiffness, oxidative stress, and inflammation in renal transplant patients?
This study protocol outlines a randomized controlled trial to evaluate whether astaxanthin supplementation can reduce arterial stiffness, oxidative stress, and inflammation in renal transplant recipients.
Answers are grounded in this paper and cite their sources.
Planned RCT will test astaxanthin for vascular and inflammatory benefits in renal transplant recipients; leaves open efficacy until completion.
BACKGROUND: There is evidence that renal transplant recipients have accelerated atherosclerosis manifest by increased cardiovascular morbidity and mortality. The high incidence of atherosclerosis is, in part, related to increased arterial stiffness, vascular dysfunction, elevated oxidative stress and inflammation associated with immunosuppressive therapy. The dietary supplement astaxanthin has shown promise as an antioxidant and anti-inflammatory therapeutic agent in cardiovascular disease. The aim of this trial is to investigate the effects of astaxanthin supplementation on arterial stiffness, oxidative stress and inflammation in renal transplant patients. METHOD AND DESIGN: This is a randomised, placebo controlled clinical trial. A total of 66 renal transplant recipients will be enrolled and allocated to receive either 12 mg/day of astaxanthin or an identical placebo for one-year. Patients will be stratified into four groups according to the type of immunosuppressant therapy they receive: 1) cyclosporine, 2) sirolimus, 3) tacrolimus or 4) prednisolone+/-azathioprine, mycophenolate mofetil or mycophenolate sodium. Primary outcome measures will be changes in 1) arterial stiffness measured by aortic pulse wave velocity (PWV), 2) oxidative stress assessed by plasma isoprostanes and 3) inflammation by plasma pentraxin 3. Secondary outcomes will include changes in vascular function assessed using the brachial artery reactivity (BAR) technique, carotid artery intimal medial thickness (CIMT), augmentation index (AIx), left ventricular afterload and additional measures of oxidative stress and inflammation. Patients will undergo these measures at baseline, six and 12 months. DISCUSSION: The results of this study will help determine the efficacy of astaxanthin on vascular structure, oxidative stress and inflammation in renal transplant patients. This may lead to a larger intervention trial assessing cardiovascular morbidity and mortality. TRIAL REGISTRATION: ACTRN12608000159358.
No takes yet. Share an insight, caveat, or question.
Fassett et al. (2008) conducted an RCT in Renal transplant (n=66). Astaxanthin vs. Placebo was evaluated on Changes in arterial stiffness (aortic pulse wave velocity), oxidative stress (plasma isoprostanes), and inflammation (plasma pentraxin 3). Astaxanthin supplementation will be evaluated against placebo for its effects on arterial stiffness, oxidative stress, and inflammation in a planned randomized controlled trial of 66 renal transplant recipients over one year.
Synapse has enriched 10 related papers. Consider them for comparative context: